Immune Thrombocytopenia Management and Pathogenesis

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by accelerated platelet destruction and impaired platelet production. Pathogenesis involves autoantibody-mediated opsonisation of platelets, Fc-dependent phagocytosis by splenic macrophages and Fc-independent clearance pathways such as desialylation with hepatic removal via asialoglycoprotein receptors. CD4+ T helper cells support autoantibody-secreting plasma cells, while CD8+ cytotoxic T cells can induce platelet apoptosis and desialylation. Cytokine imbalances and Fc receptor polymorphisms further modulate disease severity. Clinically, ITP ranges from asymptomatic thrombocytopenia to life-threatening bleeding. Management aims to achieve haemostatic platelet counts with minimal toxicity. First-line therapy usually comprises corticosteroids and intravenous immunoglobulin to suppress autoantibody production and block Fcγ receptor engagement. Second-line options include splenectomy, anti-CD20 monoclonal antibodies and thrombopoietin receptor agonists that stimulate megakaryocyte differentiation and platelet release. Emerging treatments target B-cell receptor signalling, neonatal Fc receptor pathways and complement activation. Predictive algorithms and stem cell therapies are under evaluation to personalise care. Ongoing research seeks to refine mechanistic insights, optimise long-term remission and improve patient quality of life, emphasising a shift towards precision medicine in ITP.

Research from Nature Portfolio

Recent studies have delineated novel clearance pathways and refined therapeutic approaches. Landmark work has established desialylation as a key mechanism of platelet removal: neuraminidase-mediated loss of sialic acid exposes glycan ligands recognised by hepatic asialoglycoprotein receptors, highlighting sialidase inhibition as a potential treatment for refractory cases. A comprehensive meta-analysis of thrombopoietin receptor agonists confirmed their ability to increase durable platelet responses and reduce bleeding events while maintaining a favourable safety profile. Mechanistic investigations have further shown that CD8+ cytotoxic T lymphocytes drive platelet desialylation through neuraminidase-1 translocation, linking cellular immunity to non-classical clearance and suggesting combined immunomodulatory and anti-desialylation strategies may enhance remission rates.

Immune Thrombocytopenia Management and Pathogenesis publication trend

The graph below shows the total number of articles in immune thrombocytopenia management and pathogenesis across all publications each year (not limited to Nature Index journals).

Technical terms

Autoantibody: Immunoglobulin produced against one’s own platelet antigens, leading to opsonisation and accelerated clearance.

Desialylation: Enzymatic removal of sialic acid residues from platelet surface glycoproteins, triggering hepatic clearance via asialoglycoprotein receptors.

Thrombopoietin receptor agonists (TPO-RAs): Small molecules or peptides that mimic thrombopoietin, promoting megakaryocyte maturation and platelet production.

Neonatal Fc receptor (FcRn): Receptor responsible for IgG recycling; targeted to accelerate degradation of pathogenic autoantibodies.

Megakaryocyte: Large bone marrow cell that produces platelets through cytoplasmic fragmentation.

References

1. Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP). Journal of Clinical Medicine (2017).
2. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nature Communications (2015).
3. CD8+ T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. Scientific Reports (2016).
4. Emerging Concepts in Immune Thrombocytopenia. Frontiers in Immunology (2018).
5. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis. Scientific Reports (2016).
6. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal Transduction and Targeted Therapy (2024).
7. How we treat primary immune thrombocytopenia in adults. Journal of Hematology & Oncology (2023).
8. A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study. Science Bulletin (2023).